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Summary 
Immunization with the retinal interphotoreceptor retinoid-binding protein (IRBP) induces in 
a variety of animals an inflammatory eye disease, experimental autoimmune uveoretinitis (EAU). 
We have previously shown that sequence 1181-1191 of bovine IRBP (BOV 1181-1191) is immuno- 
dominant and highly uveitogenic and immunogenic in Lewis rats.  Sequence 1181-1191 of the 
rat IRBP (RAT 1181-1191) differs from BOV 1181-1191 by two residues,  at positions 1188 and 
1190, that are pivotal for the immunological activity of the bovine epitope. Here we show that, 
unlike its bovine homologue, RAT 1181-1191 did not induce EAU or an immune response in 
Lewis rats.  The immunological inactivity of RAT 1181-1191 in Lewis rats is due at least in part 
to its poor affinity toward the antigen-presenting cells of these rats,  as shown by its failure to 
compete with binding of BOV 1181-1191 to Lewis adherent spleen cells.  Moreover, unlike all 
other known autologous homologues of immunopathogenic epitopes, RAT 1181-1191 was not 
recognized by lymphocytes sensitized against BOV 1181-1191 and failed to stimulate proliferation, 
uveitogenic capacity or signal transduction in these cells. These findings thus suggest that RAT 
1181-1191 is not a likely target for lymphocytes sensitized against BOV 1181-1191 in the process 
in which these cells recognize IRBP in the rat eye and trigger the inflammatory reaction of 
EAU. Our data further suggest that the target for the disease-inducing lymphocytes is sequence 
273-283 of the rat IRBP: (a) sequence 273-283 is highly conserved and is identical in the bovine 
and rat proteins;  (b) determinant 273-283  is a "repeat" of 1181-1191 in the fourfold structure 
of IRBP and shares seven residues with BOV 1181-1191; (c) rat peptide 273-283  is recognized 
by lymphocytes sensitized against BOV 1181-1191 and stimulates them for proliferation and for 
acquisition of uveitogenicity; and (d) moreover, sequence 273-283  is superior to BOV 1181-1191 
in its capacity to generate uveitogenicity in lymphocytes sensitized against this bovine peptide. 
The present study thus describes for the first time a system in which an autologous homologue 
of an immunopathogenic epitope is inactive and a "surrogate" determinant apparently serves 
as the target for lymphocytes sensitized against the immunopathogenic peptide. 
X 
enogeneic organ-specific antigens are commonly used 
to induce experimental autoimmune diseases.  In the 
majority of systems, the xenogeneic antigens are more active 
than their autologous homologues (1, 2),  presumably due 
to  the tolerance toward most  of the latter antigens.  It  is 
noteworthy, however, that analysis of the known major im- 
munopathogenic determinants of organ-specific antigens has 
shown close similarity or even identity between the sequence 
of xenogeneic and autologous epitopes and, as expected, strong 
antigenic cross-reactivity between them (1-5). 
Experimental autoimmune uveoretinitis (EAU) 1 is an in- 
1Abbreviations used in  this paper: EAU, experimental autoimmune 
uveoretinitis; IRBP, interphotoreceptor  retinoid-binding protein; S.I., 
stimulation index. 
flammatory eye disease that can be induced in a variety of 
species by immunization with ocular-specific antigens (6, 7). 
EAU resembles certain uveitic conditions in humans and is 
considered a model for these diseases (7-9). One of the uv- 
eitogenic antigens is interphotoreceptor retinoid-binding pro- 
tein (IRBP), a glycoprotein of 140 kD that localizes  in the 
retina and participates in the transport of retinoids between 
the neural retinal layers and the pigment epithelium (10). In 
previous studies we have identified sequence 1181-1191 of 
bovine IRBP (BOV 1181-1191) as the core of an epitope that 
is immunodominant in Lewis rats and is highly uveitogenic 
and immunogenic in these rats  (11). Sequence analysis  of 
IRBP revealed that  this protein exhibits a fourfold repeat 
structure, with partial homology among the four repeats (12). 
One of the three repeats of BOV  1181-1191, at  sequence 
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to be uveitogenic  and  immunogenic  in  Lewis rats  (13). 
Recent analysis of the sequence of rat IRBP revealed that 
the rat peptide  1181-1191  (RAT  1181-1191)  differs from its 
bovine homologue by two residues,  at  1188  and  1190  (14). 
Both residues were shown in a previous study (15) to be piv- 
otal for the immunological  activities of BOV  1181-1191  in 
the Lewis rat. The present study examined the immunolog- 
ical activities of RAT 1181-1191  and analyzed the unique fea- 
tures of the immunopathogenic process initiated by BOV 1181- 
1191. Interestingly, T  cells sensitized against BOV 1181-1191 
did not cross-react with the RAT  1181-1191  in all tested in 
vitro assays, but rather, they recognized and were stimulated 
by another rat epitope, 273-283.  These observations are in- 
terpreted  to suggest  that  peptide  273-283  is the  target for 
these lymphocytes in their initiation of the inflammation pro- 
cess in  the  eye. 
Materials  and  Methods 
Ag.  Peptides were synthesized using the t-Boc chemistry (16), 
on a peptide synthesizer (model 430A; Applied Biosystems, Inc., 
Foster City,  CA).  Peptides  were purified by preparative reverse 
phase HPLC and characterized by analytical HPLC,  amino acid 
analysis, and plasma desorption ionization mass spectroscopy. The 
sequence of the  different peptides  used  in  this  study and  their 
designation are detailed in Table 1. Biotinylated peptide Biotin-GG- 
(BOV  1179-1191) was synthesized by solid phase method.  Two 
glycine residues were added to serve as a spacer. Biotin was coupled 
using BOP/hydroxybenzotriazol in dimethylsulphoxide in manual 
mode. The peptide was purified by HPLC and characterized  by mass 
spectroscopy.  The biotinylated peptide is recognized by BOV 1181- 
1191-specific  T  cell  line in in vitro proliferation assay (data not 
shown). 
Isolation of  Rat lRBP cDNA and DNA Sequence Analysis.  RN A 
was isolated from Lewis rat retinas and reverse transcribed PCR 
was carried  out  essentially as described  (17).  PCR  primers,  5'- 
ACAAGGATGTGGTGGTCCTCACCA-3'  corresponding to mouse 
IRBP nucleotides  556-580  and 5'-TCAAAGCGCAGGTAGCC- 
Table  1.  IRBP Synthetic Peptides Used in This Study 
Peptide  Sequence* 
BOV  1179-1191 
BOV  1181-1191 
Tl188 
Nl190 
RAT  1179-1191' 











* The amino acid sequence numbering is according to Borst et al. (12). 
Residues in bold are different from bovine sequence 1179-1191. 
* According to reference 14 and verified in our laboratory (our unpub- 
lished data). 
-~ Identical in the rat and bovine IRBP; the rat sequence was determined 
as described in Materials and Methods. 
CACATTGC-Y, complementary to mouse IRBP nucleotides 1190- 
1214 (EMBL/GenBank/DDBJ accession no. Zl1813) were used to 
amplify the rat cDNA fragment homologous to bovine IRBP amino 
acids 271-283.  The DNA fragment was blunt-ended by addition 
of DNA polymerase (Klenow fragment) and dNTPs at 37~  for 
30 min and was cloned into the SmaI site of Bluescript [KSII +] 
sequencing  vector (Stratagene,  La Jolla, CA). DNA sequencing was 
performed by the dideoxynucleotide  chain termination method using 
T3/T7 promoter primers and Sequenase sequencing system (United 
States  Biochemical Corp.,  Cleveland,  OH). 
Animals.  Male inbred Lewis rats,  8-11-wk-old, were supplied 
by Charles River Breeding Laboratories, Inc. (Raleigh,  NC). 
Immunization.  The rats were immunized by a single injection 
of 1:1 emulsion of the peptides in PBS and CFA, containingMycobac- 
terium tuberculosis H37Ra at 2.5 mg/ml. The emulsion was injected 
into the left hind footpad in a volume of 0.1 ml containing various 
amounts  of peptides.  Killed Bordetella pertussis bacteria  (lot  94; 
Michigan Department of Public Health, Lansing, MI) were injected 
intravenously,  101~ organisms/rat, concurrently with the immu- 
nization. 
Disease Monitoring and Assessment.  Immunized rats were exam- 
ined daily for clinical ocular changes (18); occurrence and severity 
of the disease were verified by histology (18). The severity of the 
changes was graded on a scale of 0-4, based on the intensity of 
the inflammatory changes rather than on specific disease features, 
because diseased rats usually developed panuveitis  that affected most 
ocular tissues. 
Lymphocyte Proliferation Assay.  Draining LN cells were obtained 
12-16 d after immunization and their proliferative responses  were 
measured as described in detail elsewhere (19). Briefly, lymphocytes 
were cultured  in  triplicate  in  flat-bottom microplates,  with  or 
without  the  tested  Ag,  3  x  10s/0.2  ml/well  in  RPMI  1640 
medium supplemented with 1% normal rat serum, and 2-ME at 
5  x  10 -5 M. The total incubation time was 96 h, with the pulse 
of [3H]thymidine (0.5 #Ci/10/~l/well) given during the last 16 h. 
Data are presented as stimulation index (5.I.) values  (mean cpm 
in cultures with stimulus/mean cpm in control cultures without 
stimulus). 
Cell Line Responses.  A T lymphocyte cell line specific for BOV 
1181-1191 was established from sensitized lymph node cells, as de- 
scribed in detail elsewhere (19). The line cells were tested for prolifer- 
ation after 7 d of incubation in IL-2-containing medium. Prolifera- 
tion assay was performed as described in  reference 19.  In brief, 
2  x  104 line cells and 5  x  105 irradiated thymus ceils (being used 
as  APCs)  were incubated  in  0.2  ml supplemented  RPMI  1640 
medium. Cells were incubated for 72 h and pulsed with [3H]thy- 
midine during  the last  16 h. 
Inositol Phosphates Accumulation.  Generation of water-soluble 
inositol phosphates in the BOV 1181-1191-specific cell line was mea- 
sured using the method of Jenkins et al. (20) with modifications. 
Briefly, line cells at 107/ml were incubated for 7 h in inositol-free 
DMEM (Biofluids, Inc., ILockville, MD), with 10% dialyzed FCS, 
1% glutamine, and 50 #Ci/ml myo-[2-3H]inositol (17.8 Ci/mM; 
New England Nuclear, Boston, MA). Labeled cells were washed 
lx  with PBS and suspended  at 106 cells/10 ml medium consisting 
of RPMI 1640 (Biofluids Inc.), 10% FCS, 10 mM LiC1, along with 
the antigens as indicated, at 20 #M, and APCs (irradiated thymus 
cells) at 20  x  106/10 ml. After a 20-min incubation the assay was 
terminated by the addition of a 750-#1  solution of a 1:2 vol/vol 
chloroform/methanol,  followed by a 500 #1 1:1 vol/vol mixture 
of chloroform/water. After a 5-s vortex, each sample was centrifuged 
at 500 g for 5 min. 650/~1 of the upper aqueous phase was trans- 
ferred to  an  anion  exchange resin column  (AG  1-X8;  Bio-Rad 
134  A Pathogenic Autoimmune Process Targeted at a Surrogate Epitope Laboratories, Inc., Hercules, CA) that was subsequently washed 
3 x  with 1 ml H20. The columns were then washed 3 x  with 
1 ml of 5 mM inositol solution. The inositol phosphates were eluted 
with a 1.5 ml solution of I M sodium formate and 0.1 M formic 
acid.  Radioactivity  was  measured  after  addition  of  10  ml  of 
Hydrofluor (National Diagnostics Inc., Atlanta, GA), using a scin- 
tillation  counter (Beckman Instruments,  Inc.,  Fullerton,  CA). 
Results were recorded as mean cpm values in duplicate. 
Binding of  Bovine 1179-1191 to Adherent Spleen Cells.  Spleen  cells 
were treated with ACK lysing buffer to lyse erythrocytes. After 
triple washing, cells were suspended in RPMI 1640 medium and 
incubated in petri dishes (100 x  15 mm) at 37~  for 1 h. After 
incubation, plates were washed three times with warm RPMI 1640 
and adherent cells were collected using cell scraper and cold (4~ 
RPMI 1640. 
Adherent cells (2.5  x  106/ml) were incubated with biotinylated 
analog of BOV 1179-1191 (10/~M) at 37~  for 20 h. To inhibit 
binding nonbiotinylated peptides or rat MHC class II antibodies 
were coincubated at various concentrations with cells and labeled 
peptide.  Cells were  washed  three  times  with  cold  (4~  1% 
BSA/PBS and were incubated with Fluorescein-UltraAvidin  (Leinco 
Technologies, St. Louis, MO) at a concentration of 0.5/zg/100/xl 
of cells in 0.1% BSA/PBS for 45 min at 4~  Cells were washed 
three times with the same buffer and analyzed by flow cytometry 
using a FACScan  |  (Becton Dickinson & Co., Mountain View, CA) 
and Lysys II software. To measure the relative binding,  10,000 
propidium iodide-excluding viable cells were gated. Binding of la- 
beled peptide was assessed as percent of cells having fluorescence 
higher than background (cells  without biotinylated  peptide). Specific 
binding of the unlabeled peptides was assessed by competition and 
expressed as percent inhibition of biotinylated peptide binding in 
the absence  of competitors: Percent Inhibition  =  100- [(Binding 
with competitors  -  background)/(Binding  without competitors 
-  background)  x  100]. Specificity of binding was demonstrated 
by competition with anti-MHC class II monoclonal antibodies. 
Binding of the biotinylated peptide is inhibited up to 60% by anti- 
I-A antibody (OX-6) but not influenced at all by anti I-E antibody 
(ox-17). 
Adoptive Transfer of Disease.  Draining  lymph node cells from 
immunized rats were collected 14 d after immunization  and were 
used for adoptive transfer of EAU after incubation with the pep- 
tides. The procedure was similar to that used in our previous studies 
(21, 22). Briefly, lymph node cells were incubated with the pep- 
tides (10/zM), in aliquots of 4  x  106 in 12-well duster plates. 
After incubation for 3 d the cells were collected, washed, and in- 
jected intravenously into naive recipients. Development of disease 
was monitored  and severity of changes was assessed as described 
above. 
Results 
RAT 1181-1191 Is Nonuveitogenic  in Lewis Rats.  Table 2 
summarizes  data  of several  experiments  that  determined 
the uveitogenicity of BOV 1181-1191, RAT 1181-1191, and the 
two peptide analogs, Tl188 and Nl190 (see Table 1 for the 
sequences of peptides used in this study). In accord with our 
previous studies (11, 15), BOV 1181-1191 was highly uveito- 
genic, producing severe ocular changes with early onset in 
all immunized rats.  In contrast, no disease was detected in 
any of the rats immunized with RAT 1181-1191 at the high 
tested dose of 200 nmol/rat.  A low level of uveitogenicity 
was  exhibited  by  peptide  Tl188,  that  induced  EAU  of 
moderate severity in approximately two thirds of the rats, 
whereas the other peptide analog, Nl190, was only slightly 
less uveitogenic than BOV  1181-1191. 
RAT 1181-1191 Is Nonimmunogenic and Nonantigenic in Lewis 
Rats.  Immunogenicity of the tested peptides was assessed 
by their capacity to induce cellular immunity, measured by 
the lymphocyte proliferation assay. As seen in Fig.  1, BOV 
1181-1191 was highly immunogenic, inducing responses with 
S.I.  levels of >20.  In contrast,  no detectable response was 
elicited by RAT 1181-1191. A moderate cellular response was 
also induced by analog Tl188, whereas peptide Nl190 stimu- 
lated a low-level response. LN cells of rats immunized with 
each of the four peptides were also tested for their response 
toward the other three tested peptides (Fig.  1). RAT 1181- 
1191 was not recognized by any of the LN cells, whereas var- 
ious levels of cross-reactivity were observed among the other 
three peptides. LN cells  sensitized against BOV 1181-1191 
cross-reacted well with Nl190 and marginally with Tl188. 
Lymphocytes sensitized against Tl188, on the other hand, 
did not cross-react with any other peptide, whereas cells sen- 
sitized against  Nl190 responded against BOV 1181-1191 with 
low levels, similar to those of the response to Nl190 itself. 
It is of note that whenever reactive, BOV 1181-1191 stimu- 
Table 2.  Uveitogenicity in Lewis Rats of the Bovine and Rat Peptides 1181-1191 and Their Analogs* 
EAU 
Onset day  Severity 
Peptide*  Incidence  (mean)S  (mean)S 
BOV 1181-1191  12/12  10.0  2.8 
RAT 1181-1191  0/6  -  0 
Tl188  11/16  13.7  1.5 
Nl190  3/3  11.0  2.5 
* The peptides were injected at 200 nmol/rat, as described in Materials and Methods. 
See Table 1 for the sequences of the peptides. 
S  The mean values in rats with disease. 
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Figure  1.  lmmunogenicity of the bovine and rat peptides 1181-1191 and 
their analogs: proliferative responses of LN ceils from rats immunized with 
200 nm/rat of: (A) BOV 1181-1191; (B) RAT 1181-1191; (C) Tl188; (D) 
Nl190. The tested antigens  include  the immunizing peptides  and their 
analogs.  The data are presented  as stimulation index values. The mean 
cpm +_ SE values in the control cultures with no antigen were: (A) 1841 
_+  106; (B)  1726  _+  399;  (C)  1955  _+  351; (D)  1219  _+  176. 
lated proliferation at concentrations lower by approximately 
three orders of magnitude than the active concentrations of 
the other two peptides.  This observation is interpreted to 
show that BOV 1181-1191 interacts with the APCs with much 
higher af~nity than the two analogs, although a higher af~nity 
of the peptide-MHC complex for the TCR cannot be ex- 
cluded. 
RAT 1181-1191 Interacts Poorly with Lewis Rat Spleen Ad- 
herent Cells.  The possibility that the inactivity of RAT 1181- 
1191 in Lewis rats is due at least in part to its poor interac- 
tion with the MHC on the APCs of these rats was tested 
by probing the capacity of this peptide to competitively in- 
hibit the binding of biotin-labeled BOV 1179-1191 to adherent 
cells of Lewis rats. As shown in Fig. 2, RAT 1181-1191 was 
found to be inactive in this assay. In contrast, this binding 
was inhibited by "~70% in the presence of the same concen- 
tration of unlabeled BOV 1181-1191. A moderate inhibition 
of the binding of BOV  1181-1191 was achieved by analog 
Tl188, whereas analog Nl190 was essentially inactive in this 
assay. A low level of activity was also exhibited by peptide 
IRBP 273-283.  This peptide, a "repeat" of determinant 1181- 
1191 (13), shares seven residues with BOV 1181-1191 (Table 
1),  and cross-reacts with it  (reference 13 and data shown 
below). 
RAT 1181-1191 Does Not Induce Generation of lnositol Phos- 
p~tes in BOV 1181-1191-specific T Cells.  To exclude the pos- 
sibility that RAT 1181-1191 stimulates BOV 1181-1191-specific 
cells in ways other than proliferation we examined inositol 
phosphates production, which follows the antigen receptor 
occupancy in T  cells (20, 23). As shown in Fig. 3, incuba- 
tion of BOV 1181-1191-specific T cells with BOV 1181-1191 
and accessory cells caused profound accumulation of inositol 
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Figure  2.  Inhibition of binding of biotinylated  BOV 1179-1191 m ad- 
herent spleen cells by unlabeled peptides (see Table 1 for sequences). The 
assay was performed as described in Materials and Methods. Labeled BOV 
1179-1191 was incubated  with cells at the concentration  of 10/~M, unla- 
beled peptides  were added at  100 ~M. 
phosphates. In contrast, incubation of cells with RAT 1181- 
1191 did not generate any detectable increase in production 
of inositol phosphates over the background level. The ina- 
bility of RAT 1181-1191 to induce generation of inositol phos- 
phates practically rules out the possibility of its functional 
interaction with T  cells specific to the BOV  1181-1191. 
IRBP 273-283 Is a Potential Target for Pathogenic Lympho- 
cytes, Sensitized Against BOV 1181-1191.  The findings that 
RAT 1181-1191 is nonuveitogenic in Lewis rats (Table 2) and 
lymphocytes sensitized against BOV 1181-1191 do not recog- 
nize it (Fig.  1) make it unlikely that this rat determinant is 
the target for these lymphocytes in their initiation of the EAU 
process.  It is conceivable, therefore, that the sensitized lym- 
phocytes recognize another epitope in the rat eye. The fol- 
lowing data provide evidence to support the hypothesis that 
IRBP 273-283  is the putative surrogate epitope. 
Sequence 273-283  is highly conserved (24) and our anal- 
ysis of the rat molecule revealed that, unlike 1181-1191, se- 
quence 273-283 is identical in bovine and rat IRBP (Egwuagu, 
C. E., unpublished data). We have previously found a moderate 
level of cross-reactivity between bovine peptides 271-283 and 
1179-1191 using LN cells from immunized rats (13). As shown 
in Fig. 4 lymphocytes of a cell line specific for BOV 1181- 
1191 recognized IRBP 273-283  and proliferated with a S.I. 
as high as 100 when stimulated with it in culture. In con- 
RAT1181-1191. 
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Figure  3.  Inositol phosphates  generation  upon incubation  of a BOV 
1181-1191-specific cell line with RAT 1181-1191 or BOV 1181-1191 at 20 
/xM, in the presence of APCs. Total inositol phosphates  were measured 
after a 20-min incubation,  as detailed in Materials  and Methods. 
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Figure 4.  Recognition of the RAT 1181-1191 and IRBP 273-283 by 
a cell line-specific  for BOV 1181-1191. The response against 1181-1191 is 
shown for comparison. The mean cpm -+ SE value in unstimulated con- 
trol cultures was 235  _+  22. 
trast, RAT 1181-1191 did not stimulate any detectable response 
in these cells. 
The notion that peptide 273-283 is the target for the BOV 
1181-1191-specific EAU-inducing lymphocytes was supported 
in particular by data produced by the assay in which uveitoge- 
nicity is generated in lymphocytes by stimulation in culture 
with various antigens; only molecules recognized by the lym- 
phocytes are stimulatory in this assay (21).  Table 3 summa- 
rizes a series of experiments in which LN cells from rats im- 
munized  with  BOV  1181-1191  were  cultured  with  BOV 
1181-1191, RAT 1181-1191, and IRBP 273-283. In addition, 
the corresponding 13-met peptides of these determinants were 
tested, in order to examine the activity of peptides at a size 
optimal for the interaction with APCs (25). The system used 
here yielded lymphocytes with unusually strong uveitogenic 
activity; mild disease was produced even by cells cultured with 
no stimulant, when tested at the high number of 30  x  106 
(for comparison with other systems, see references 13  and 
15). Lymphocytes stimulated in culture with RAT 1181-1191 
or RAT  1179-1191  were just marginally more uveitogenic 
than  the controls cultured  with no  stimulant,  while cells 
stimulated with the other peptides were profoundly more 
uveitogenic. Remarkably, peptides 273-283 or 271-283 were 
found superior to peptides BOV  1181-1191  or BOV  1179- 
1191 in their capacity to generate uveitogenicity in lympho- 
cytes sensitized against BOV  1181-1191.  Thus,  at the high 
Table  3.  Generation  of Uveitogenicity in LN Cells from Rats Immunized with BOV 1181-1191" 
EAU 
Cells injected/  Day of onset  Severity 




BOV  1181-1191 




30  2/5  5.5  0.8 
5  0/6  --  -- 
30  3/5  5.0  1.0 
5  0/3  --  0 
2  0/2  --  0 
3O  5/5  4.0  1.5 
5  0/3  --  0 
2  0/3  --  0 
30  9/9  4.0  1.2 
5  6/6  5.5  0.7 
2  2/4  --  0.5 
30  5/5  4.0  1.4 
5  3/3  6.0  1.0 
2  2/2  --  0.8 
30  4/4  3.5  2.5 
5  6/6  5.2  1.3 
2  4/4  6.0  0.9 
30  8/8  2.4  2.7 
5  3/3  3.7  2.2 
2  3/3  4.0  1.7 
* The primed LN cells were cultured with the different peptides, as described in Materials and Methods, and tested for uveitogenicity  in naive recipients. 
* The mean values of the rats with disease. 
137  Kozhich  et al. cell numbers, 30 and 5  x  106, lymphocytes stimulated by 
the repeat peptides 273-283  or 271-283  produced EAU that 
developed earlier and was much more severe than the disease 
induced by cells stimulated with BOV  1181-1191 or BOV 
1179-1191. At the low cell number of 2  x  106, cells stimu- 
lated with the repeat peptides induced EAU in all recipients, 
detected both clinically and histologically, whereas the BOV 
peptides produced disease in only a portion of recipients and 
with changes detected only by histological examination. 
Discussion 
Data recorded here describe the unique features of the patho- 
genic autoimmune system initiated in Lewis rats by IRBP 
peptide 1181-1191. This sequence of bovine IRBP (BOV 1181- 
1191) is immunodominant in Lewis rats and is highly uveito- 
genic and immunogenic in these animals (11). The rat homo- 
logue of this sequence (RAT 1181-1191) on the other hand, 
was found to be completely immunologically inactive in Lewis 
rats (Table 2 and Fig.  1). The inactivity of RAT 1181-1191 
is in contrast to observations in other known systems in which 
the autologous homologues of xenogeneic immunopatho- 
genic peptides are pathogenic and immunogenic (1-5). The 
striking difference between RAT 1181-1191 and BOV 1181- 
1191 is attributable to different amino acids at positions 1188 
and 1190 of the two peptides. We have previously shown that 
both residues are pivotal for the immunological potency of 
BOV 1181-1191 in Lewis rats, with the valine at position 1188 
participating in the interaction of the peptide with the TCR 
on lymphocytes and the aspartic acid at 1190 interacting with 
the MHC on APCs (15). It is assumed, therefore, that sub- 
stitution with threonine at 1188 and with asparagine at 1190 
renders RAT 1181-1191 completely inactive in the Lewis rat. 
Indeed, substantial reduction in activity was observed even 
by single substitution at either residue 1188 or 1190. Thus, 
in line with their corresponding alanine analogs,  tested in 
our previous study (15), peptide Tl188 showed minimal or 
no cross-reactivity with BOV 1181-1191 (Fig.  1 A), whereas 
Nl190 exhibited poor binding to Lewis rat APC (Fig. 2) and 
was recognized by lymphocytes sensitized against BOV 1181- 
1191 only at exceedingly high concentrations (Fig.  1). The 
current results can thus be explained by these different func- 
tional roles of residue 1188 and 1190. Substitution with threo- 
nine at 1188 alters the TCR recognition rather than MHC 
binding, so the analog competes (Fig. 2) and is immunogenic 
(Fig.  1 C), but the induced T  cells do not crossreact with 
BOV  1181-1191 (Fig.  1 C).  In contrast,  substitution  with 
asparagine at 1190, which affects binding to MHC (Fig.  2) 
but not TCR recognition, strongly reduces the immunoge- 
nicity, but the T  cells that are elicited react to BOV  1181- 
1191 at concentrations lower than those of the imrnunogen 
Nl190, presumably because BOV 1181-1191 binds with higher 
affinity to the MHC molecule but looks similar to the TCR 
(Fig.  1 D). 
The uniqueness of the system studied here is further depicted 
by the failure of RAT 1181-1191 to be recognized by and to 
stimulate  lymphocytes sensitized against  BOV  1181-1191. 
Thus, lymphocytes sensitized against BOV 1181-1191 did not 
respond to RAT 1181-1191 as tested by proliferation (Fig. 
1), stimulation of uveitogenicity (Table 3) and even failed to 
induce detectable signal transduction, assayed by generation 
ofinositol phosphates (Fig. 3). It should be mentioned here, 
however, that despite the lack of response to RAT 1181-1191 
by lymphocytes sensitized to BOV 1181-1191 in these in vitro 
assays, it cannot be ruled out that this rat peptide can be a 
target for these lymphocytes in vivo.  In contrast to the ob- 
servations with RAT 1181-1191, autologous homologues of 
immunopathogenic xenogeneic epitopes in other systems are 
recognized by lymphocytes sensitized against the latter pep- 
tides (1-5). Moreover, since lymphocytes sensitized against 
BOV 1181-1191 should recognize an antigenic epitope in the 
rat eye in order to initiate the EAU process,  it is assumed 
that an IRBP epitope other than RAT 1181-1191 serves as 
the target for the lymphocytes sensitized against BOV 1181- 
1191. It is possible that there are more than one isoform of 
rat IRBP and sequence 1181-1191 of another isoform could 
cross-react with BOV 1181-1191. The data recorded here, how- 
ever, provide evidence to suggest that IRBP peptide 273-283 
is the putative target (surrogate) epitope. 
Sequence 273-283  is a repeat of 1181-1191 in the fourfold 
structure of IRBP (12) and in the bovine molecule the two 
determinants share seven amino acids (Table 1). In addition, 
sequence 273-283 is highly conserved and we have found that 
it is identical in the rat and bovine proteins; previous studies 
showed the identity between the bovine and human deter- 
minants (24).  Furthermore, a cross-reactivity was shown in 
our previous study between bovine peptides 271-283 and 1179- 
1191 (13) and the data recorded here now show that lympho- 
cytes sensitized against BOV 1181-1191 are stimulated by the 
273-283  determinant of rat IRBP to proliferate (Fig. 4) and 
to acquire strong uveitogenic capacity (Table 3).  The data 
recorded in Table 3 are of particular interest by showing that 
IRBP 273-283  is superior to BOV 1181-1191 in generating 
uveitogenicity in lymphocytes sensitized against the latter pep- 
tide. This observation is interpreted to suggest that incuba- 
tion in vitro with determinant 273-283 selectively stimulates 
the subpopulation of lymphocytes that recognize this epi- 
tope and these cells then effectively induce EAU, after their 
reexposure to peptide 273-283  in the eye. The population 
stimulated with BOV 1181-1191, on the other hand, is less 
uveitogenic presumably because a large portion of this popu- 
lation consists of cells  that do not recognize determinant 
273-283. 
Data recorded here shed new light on the immunological 
profiles of bovine IRBP determinants 1181-1191 and 273-283 
in Lewis rats. Our previous studies (13) with the corresponding 
13-mer peptides have shown that  1179-1191 is more active 
than 271-283 in Lewis rats by several parameters: (a) peptide 
1179-1191 is more immunodominant than 271-283, as depicted 
by the capacity of the former peptide to stimulate higher levels 
of proliferation in lymphocytes sensitized against whole IRBP; 
(b)  peptide  1179-1191  was  found  to  be  more  antigenic, 
stimulating proliferation of sensitized lymphocytes at much 
lower concentrations than peptide 271-283;  (c) peptide 1179- 
1191 stimulates cellular immunity in vivo and induces EAU 
at doses lower than those of 271-283 by 2-3 orders of magni- 
138  A Pathogenic Autoimmune  Process Targeted at a Surrogate Epitope tude. These features of peptide 1179-1191 are assumed to be 
due to the high affinity of this determinant toward the MHC 
molecules of the Lewis rat (26), an assumption that is in line 
with the data of the binding in competition assay recorded 
here (Fig. 2). Peptide 271-283, on the other hand, was previ- 
ously found to be more uveitogenic than 1179-1191 when 
tested at the high dose of 150 nmol/rat; at this dose the ocular 
changes induced by 271-283 were more severe and developed 
earlier  than those induced by peptide 1179-1191 (13). This 
observation, as well as the finding recorded here, concerning 
the superiority of peptide 271-283  in generating uveitoge- 
nicity in culture (Table 3) can now be attributed to this epi- 
tope's presumed role as the target for the EAU-inducing lym- 
phocytes. 
The putative usage of a surrogate epitope in an immuno- 
pathogenic process, as described  here, is presumably an un- 
common phenomenon. It is conceivable,  however,  that fu- 
ture studies will reveal that surrogate epitopes are used in 
other systems, in particular those in which large molecules, 
with repeated sequences,  serve as target antigens. 
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